Sometimes biggest is not "best". Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.
Sometimes biggest is not "best". Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.
The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.
A bill to decriminalize drug possession has been introduced into Congress. If passed, jurisdiction for drug classifying would move from the Justice Department to the Department of Health and Human Services.
Atai Life Sciences has re-filed with the SEC to increase its IPO financing from $100 to $246 million. It's a big deal.
Co-Founder JR Rahn has stepped down as CEO of MindMed. His replacement, Robert Barrow, brings a wealth of clinical trials experience.
Psychedelic drugs increasingly appear to be powerful medicinal tools to rebuild broken brains.
The psychedelic drug industry already has a large footprint in healthcare. And it is growing in literally every direction.
Public psychedelics companies have radically scaled-back capital raising due to low share prices. But institutional investors are still pumping large amounts of cash into private players.
The Psychedelic Drug Revolution has begun. Standing in the way are politicians and regulators, saddled with archaic anti-drug phobias. They need to be educated.
The FDA has approved the use of MDMA by therapists -- to better prepare them to administer MDMA-assisted psychotherapy.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now